MULHOUSE, France – (COMMERCIAL THREAD) – CellProthera SAS, a clinical-stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other damaged organs, has strengthened its management team to further the development of its core clinical program and the extend to new therapeutic indications.
Ibon Garitaonandia is appointed Scientific Director (CSO). His extensive experience in drug discovery and in the development of new stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years of experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the former The company will receive global regulatory approval to conduct a clinical trial based on human pluripotent stem cells for Parkinson’s disease.
Henk Streefkerk, MD PhD, assumes the role of Chief Medical Officer (CMO). He brings decades of leadership in clinical research to drive the company’s strategic development and advance its portfolio of new therapeutic solutions. After graduating from Utrecht University Medical Center, Henk worked as a clinical pharmacologist for Organon / Schering-Plow in the Netherlands. He then joined Actelion in Switzerland before occupying the positions of expert in translational medicine and then Senior Brand Safety Leader at Novartis in Basel. After Novartis, he worked as medical director and medical director of a biotech specializing in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO). Its solid history of helping businesses and start-ups evolve on their development journey is essential for CellProthera as it enters its next stage of development. Lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and taxation. He has held leadership roles at Ernst & Young for over 10 years, leading financial audits and due diligence transactions for a wide range of industrial companies and as CFO, supporting treasury and finance management. listed companies in the energy and automotive sectors.
“The arrival of these three talents – all experts in their field – within the general management team is a tremendous boost to our ambitious multi-indication development program and ideally positions us to accelerate our commercialization. Said Matthieu de Kalbermatten, President of CellProthera: “Their wealth of international experience will be useful in effectively shaping and steering the company through the next clinical and regulatory stages.
CellProthera developed a medical innovation that allows a heart damaged by a heart attack to regenerate by injecting stem cells from the patient’s own blood.
Thus, each patient becomes their own source of medicine!
The ProtheraCytes® stem cell product is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future often severe treatments, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/en/
The original source language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only and should be referenced with the source language text, which is the only version of the text intended to have legal effect.